<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416636</url>
  </required_header>
  <id_info>
    <org_study_id>116-02</org_study_id>
    <nct_id>NCT01416636</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)</brief_title>
  <acronym>CTREPH</acronym>
  <official_title>A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SciPharm SàRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SciPharm SàRL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the effect on six-minute walking test
      (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in
      patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by non-resolving
      organized thromboembolic obstructing the pulmonary vascular bed. These thrombi are resistant
      to thrombolytic therapy and chronic plasmatic anticoagulation. An increase in pulmonary
      vascular resistance (PVR), right ventricular overload, and eventually right ventricular
      failure ensue.

      The treatment of choice for CTEPH is pulmonary endarterectomy (PEA), providing a potential
      cure for the disease. However, about 50 % of patients are not candidates for surgery, mainly
      because of distal location of thromboemboli. Despite recent advances in the treatment of
      pulmonary arterial hypertension (PAH), medical treatments have not been recommended for
      inoperable CTEPH, because of the concept that a predominantly major vessel obstructive
      arteriopathy would not be suitable for vasodilators. Furthermore, a major drawback of i.v.
      prostacyclin therapy is the need for a permanent central venous access that increases the
      risk of infection (0.22-0.68 per patient per year), thrombosis and new major vessel
      thromboembolism.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-minute Walk Test Distance After 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits:
baseline (day 1)
Visit 6 (day 168)
In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Worsening</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension.
Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Maximal Borg Score During 6-minutes Walk Test</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to &gt; 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); &gt;10 MAXIMUM).
As can be seen with the scale, the higher scale values represent a worse outcome.
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.
Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.
Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope
Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Quality of Life by the MINNESOTA Questionnaire</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life.
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on N-terminal Pro-BNP Levels</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>baseline values, assessment after 12 and 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Hemodynamic Parameter (CI - Cardiac Index)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Hemodynamic Parameter (CO - Cardiac Output)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Signs &amp; Symptoms of the CTEPH</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>baseline values, assessment after 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Non-operable Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Treprostinil sodium low dose - Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm I (low dose):
Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.
Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.
This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treprostinil sodium high dose - Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.
Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.
This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil sodium</intervention_name>
    <arm_group_label>Treprostinil sodium high dose - Arm II</arm_group_label>
    <arm_group_label>Treprostinil sodium low dose - Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Subject must be competent to understand the information given in the written informed
             consent and from the investigator and must sign and date the informed consent prior to
             any study mandated procedure.

          2. Subject must be at least 18 years of age and can be of any ethnical origin

          3. Women of child bearing potential must be surgically sterile or postmenopausal
             (amenorrhea for at least 12 months) or using an acceptable form of contraception.
             Reliable contraception is defined as a method which results in a low failure rate,
             i.e., less than 1% per year when used correctly such as, implants, injectables, oral
             contraceptive medications, sexual abstinence, or a vasectomised partner.

          4. Subject must have a current diagnosis of CTEPH, as defined by the following criteria:

               -  A test result of perfusion scintigraphy and pulmonary angiography and/or
                  multislice CT not older than 6 months, consistent with the diagnosis CTEPH. In
                  case of recurrent PH after PEA, test results from before the surgery are
                  acceptable if a typical specimen was harvested during PEA substantiating the
                  diagnosis of CTEPH.

               -  A right heart catheterization, not older than 6 months, consistent with the
                  diagnosis CTEPH but specifically with a mean pulmonary artery pressure (PAPm) of
                  &gt; 25 mmHg, and a PVR of &gt; 300 dyn.s.cm-5

               -  At least three months of effective anticoagulation therapy (without improvement /
                  to exclude subacute pulmonary emboli)

          5. Subject must have CTEPH classified as severe, as defined by the following criteria:

               -  An un-encouraged 6MWT distance of between 150 and 400 meters

               -  Classification in the WHO/New York Heart Association (NYHA) functional class III
                  or IV

          6. The subject must not be suitable to undergo a PEA and is therefore defined as
             non-operable, due to at least one of the following reasons:

               -  Clot is not accessible

               -  Discrepancy between severity of PH and morphologic lesion

               -  Subject is not a good surgical candidate for other reasons:

             PVR &gt; 1500 dynes.s.cm-5 Age Comorbidity No functional lung parenchyma

               -  Unsuccessful PEA in the past with residual/recurrent CTEPH

               -  No consent for PEA given by subject

          7. Subject must be willing and able to follow all study procedures

        Exclusion:

          1. Subject with any form of pulmonary arterial hypertension or any disease known to cause
             PAH (WHO Group I)

          2. Subjects with a total lung capacity (TLC) of &lt; 70% predicted or a forced expiratory
             volume/forced vital capacity (FEV1/FVC &lt; 50%)

          3. Subject who received any prostanoids, within the 30 days before screening or be
             scheduled to receive prostanoids during the course of the study

          4. Subject with a new type of chronic therapy (a different category of vasodilator or
             diuretic) for PAH added within the last month, except anticoagulants

          5. Subject with an increased risk for hemorrhage or stroke or with a major cardiovascular
             event during the past 6 months.

          6. Unstable subjects for any reason (according to the investigators discretion)

          7. Subject who received any investigational medication within 30 days prior to the
             screening visit of this study or be scheduled to receive another investigational drug
             during the course of this study

          8. Subject with a known intolerance to any drug relevant for this trial, especially to
             Treprostinil sodium or prostanoids

          9. Subject with a history or suspicion of non compliance

         10. Subject who has any musculoskeletal disease or any other disease that would limit
             ambulation

         11. Subject with other cardiovascular, liver, renal, hematologic, gastrointestinal
             immunologic, endocrine, metabolic, or central nervous system disease that, in the
             opinion of the investigator, may adversely affect the safety of the subject and /or
             efficacy of the study drug or limit the lifespan of the subject

         12. Female who is considering pregnancy or who is pregnant and/or lactating

         13. Subject who is an investigator or any other team member involved directly or
             indirectly in the conduct of the clinical study.

         14. Subject who is an inmate of a psychiatric ward, prison or is suspected not to be able
             to give consent of his free will
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Lang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna AKH - Division Cardiology</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II. interní klinika Všeobecná fakultní nemocnice</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Carl Gustav Carus Medizinische Klinik und Poliklinik I Medizinische Fakultät der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiac and Vascular Diseases Centre for Rare Cardiovascular Diseases John Paul II Hospital</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Europejskie Centrum Zdrowia Otwock</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation. 1994 Jun;89(6):2715-21.</citation>
    <PMID>8205686</PMID>
  </reference>
  <reference>
    <citation>Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, Pepke-Zaba J, Jamieson SW, Lang I, Corris P. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):73S-80S. Review.</citation>
    <PMID>15194182</PMID>
  </reference>
  <reference>
    <citation>McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahearn G; American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul;126(1 Suppl):78S-92S. Review.</citation>
    <PMID>15249497</PMID>
  </reference>
  <reference>
    <citation>Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003 Feb 15;167(4):580-6. Epub 2002 Nov 21.</citation>
    <PMID>12446266</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 12, 2011</study_first_submitted>
  <study_first_submitted_qc>August 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <results_first_submitted>March 1, 2018</results_first_submitted>
  <results_first_submitted_qc>March 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2019</results_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treprostinil Sodium High Dose (~30ng/kg/Min)</title>
          <description>Treprostinil sodium was administered subcutaneously via an ambulatory infusion pump with continuous flow rate. Patients were uptitrated to a target dose of approx. 30ng/kg/min within the first 12 weeks and were kept on stable dose for the remaining 12 weeks study duration.</description>
        </group>
        <group group_id="P2">
          <title>Treprostinil Sodium Low Dose (~3ng/kg/Min)</title>
          <description>Treprostinil sodium was administered subcutaneously via an ambulatory infusion pump with continuous flow rate. Patients were uptitrated to a target dose of approx. 3ng/kg/min within the first 12 weeks and were kept on stable dose for the remaining 12 weeks study duration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose</title>
          <description>Treprostinil sodium high dose</description>
        </group>
        <group group_id="B2">
          <title>Low Dose</title>
          <description>Treprostinil sodium low dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.06" spread="11.16"/>
                    <measurement group_id="B2" value="60.58" spread="14.59"/>
                    <measurement group_id="B3" value="64.35" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 6-minute Walk Test Distance After 24 Weeks</title>
        <description>To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits:
baseline (day 1)
Visit 6 (day 168)
In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>All randomized subjects who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-minute Walk Test Distance After 24 Weeks</title>
          <description>To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits:
baseline (day 1)
Visit 6 (day 168)
In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.</description>
          <population>All randomized subjects who received at least one dose of study medication.</population>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.43" spread="71.29"/>
                    <measurement group_id="O2" value="3.83" spread="56.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Worsening</title>
        <description>Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension.
Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.</description>
        <time_frame>12 weeks and 24 weeks</time_frame>
        <population>All randomized subjects who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Worsening</title>
          <description>Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension.
Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.</description>
          <population>All randomized subjects who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.605</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Maximal Borg Score During 6-minutes Walk Test</title>
        <description>The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to &gt; 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); &gt;10 MAXIMUM).
As can be seen with the scale, the higher scale values represent a worse outcome.
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>For this endpoint no imputation role was applied. For 48 patients of the high dose group, as well as for the low dose group, baseline data and also 24 week data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Maximal Borg Score During 6-minutes Walk Test</title>
          <description>The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to &gt; 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); &gt;10 MAXIMUM).
As can be seen with the scale, the higher scale values represent a worse outcome.
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.</description>
          <population>For this endpoint no imputation role was applied. For 48 patients of the high dose group, as well as for the low dose group, baseline data and also 24 week data are available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="2.21"/>
                    <measurement group_id="O2" value="-0.13" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.307</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class</title>
        <description>Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.
Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.
Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope
Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class</title>
          <description>Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.
Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.
Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope
Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Quality of Life by the MINNESOTA Questionnaire</title>
        <description>This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life.
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Quality of Life by the MINNESOTA Questionnaire</title>
          <description>This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life.
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.36" spread="22.9"/>
                    <measurement group_id="O2" value="-4.63" spread="19.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.557</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on N-terminal Pro-BNP Levels</title>
        <description>baseline values, assessment after 12 and 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on N-terminal Pro-BNP Levels</title>
          <description>baseline values, assessment after 12 and 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.</description>
          <units>percentage change to baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="63.32"/>
                    <measurement group_id="O2" value="41.68" spread="104.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)</title>
        <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)</title>
          <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
          <units>dyn.s.cm^-5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-214.23" spread="324.28"/>
                    <measurement group_id="O2" value="72.96" spread="284.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.00001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Hemodynamic Parameter (CI - Cardiac Index)</title>
        <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Hemodynamic Parameter (CI - Cardiac Index)</title>
          <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
          <units>L/min/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.9"/>
                    <measurement group_id="O2" value="-0.16" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Hemodynamic Parameter (CO - Cardiac Output)</title>
        <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Hemodynamic Parameter (CO - Cardiac Output)</title>
          <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="1.47"/>
                    <measurement group_id="O2" value="-0.22" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.00008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)</title>
        <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)</title>
          <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.36" spread="8.04"/>
                    <measurement group_id="O2" value="-0.4" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)</title>
        <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)</title>
          <description>baseline values, assessment after 24 weeks
As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="5.08"/>
                    <measurement group_id="O2" value="2.87" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Signs &amp; Symptoms of the CTEPH</title>
        <description>baseline values, assessment after 24 weeks</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose</title>
            <description>Treprostinil sodium high dose</description>
          </group>
          <group group_id="O2">
            <title>Low Dose</title>
            <description>Treprostinil sodium low dose</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Signs &amp; Symptoms of the CTEPH</title>
          <description>baseline values, assessment after 24 weeks</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ascites : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascites : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthopnoea : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthopnoea : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea at rest : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea at rest : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal nocturnal dyspnoea : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal nocturnal dyspnoea : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea on exertion : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnoea on exertion : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Syncope : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Syncope : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thirst : Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thirst : Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>Treprostinil sodium high dose</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>Treprostinil sodium low dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Accute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Worsening of pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infusion site reactions</sub_title>
                <description>Infusion site reactions include inf. site abscess, inf. site erythema, inf. site haemorrhage, inf. site infection, inf. site inflammation, inf. site irritation, inf. site pruritus, inf. site rash, inf. site reaction, inf. site swelling</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain in extremities</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Worsening of Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bianca Tan</name_or_title>
      <organization>SciPharm SàRL</organization>
      <email>b.tan@scipharm.eu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

